Phase III trial shows risvutatug rezetecan improves survival in relapsed small-cell lung cancer

The randomized Phase III ARTEMIS‑008 trial demonstrated that risvutatug rezetecan (Ris‑Rez), a B7‑H3‑directed antibody‑drug conjugate, significantly prolonged overall survival compared with topotecan in patients with relapsed small‑cell lung cancer (SCLC) whose disease had progressed after platinum‑based chemotherapy. Results were unveiled today at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC). The study enrolled participants with previously treated SCLC and assigned them to receive either Ris‑Rez or standard‑of‑care topotecan, with the primary endpoint focused on overall survival.

The trial’s findings indicate a meaningful survival advantage for the antibody‑drug conjugate, positioning Ris‑Rez as a potential new therapeutic option for a population with limited treatment choices. investigators highlighted the robust statistical significance of the survival benefit and reported a safety profile consistent with earlier phase data. The presentation at WCLC underscores the growing interest in targeting B7‑H3 in oncology and may inform forthcoming regulatory and clinical decisions regarding the adoption of Ris‑Rez for relapsed SCLC.